Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Sees Significant Increase in Short Interest

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 85,580 shares, a growth of 29.8% from the January 15th total of 65,924 shares. Based on an average daily volume of 69,840 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 69,840 shares, the days-to-cover ratio is currently 1.2 days.

Sandoz Group Price Performance

Sandoz Group stock opened at $86.78 on Wednesday. The stock’s 50 day moving average price is $77.05 and its 200 day moving average price is $68.02. Sandoz Group has a 1-year low of $35.61 and a 1-year high of $87.57. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.82 and a current ratio of 1.29.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.